Related Experiment Video
Updated: May 5, 2026

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
Published on: July 20, 2022
Liver Maximum Capacity (LiMAx) Test Is a Promising Tool to Predict Fibrosis and Cirrhosis in Chronic Liver Disease: A
1Ear, Nose and Throat, West Suffolk National Health Service (NHS) Foundation Trust, Bury St Edmunds, GBR.
Abstract:
Patients affected with chronic liver disease (CLD) are increasing and our ability to manage them is hindered by the lack of a simple and accurate test for measuring the liver function. LiMAx is a novel, non-invasive tool that measures the metabolic capacity of hepatocytes by measuring the ratio of 13CO2 to 12CO2 exhaled following the administration of isotope-labelled methacetin. This systematic review assessed the ability of LiMAx to diagnose and stage steatosis and fibrosis and predict 90-day mortality in CLD. Literature search was carried out using Embase and Medline accessed via Ovid, Web of Science, and Cochrane Library. The inclusion criteria were case-control or cohort studies in all languages. Statistical analysis for the diagnostic accuracy of LiMAx and the diagnostic accuracy of other available methods for clinically relevant milestones in CLD was carried out by pooling the area under the receiver operating characteristic curve (AUROC) and correlation coefficients. A total of seven studies met the inclusion criteria and data were extracted into Microsoft Excel tables with a total number of 1623 participants. LiMAx performed significantly better than transesophageal echocardiography (TE), Fibrosis-4 (FIB-4) test, aspartate transaminase to alanine transaminase ratio (AAR), spleen size and aspartate aminotransferase-to-platelet ratio index (APRI) at predicting 90-day mortality (AUROC=0.82). LiMAx is superior in detecting cirrhosis (AUROC=0.92) and at identifying fibrosis for patients with non-MASLD (metabolic dysfunction-associated steatotic liver disease) aetiology. Furthermore, LiMAx had the strongest (negative) correlation with liver histopathology (r=-0.75). It was found that the LiMAx test is a promising point-of-care approach for the detection of cirrhosis and fibrosis. However, large-scale studies across all liver aetiologies and stages are necessary to confirm the utility of LiMAx in clinical practice.
More Related Videos
06:09Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology